Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCL-161 in Myelofibrosis
NCT02098161Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2014
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LCL161 in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2014; status: completed.
02
Drugs
LCL161
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT02098161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098161.